The InterVitaminK Trial - Effects of Vitamin K Supplementation on Cardiovascular, Metabolic, and … (NCT05259046) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
The InterVitaminK Trial - Effects of Vitamin K Supplementation on Cardiovascular, Metabolic, and Bone Health
Denmark450 participantsStarted 2022-06-21
Plain-language summary
The purpose of this study is to examine the effect of menaquinone-7 (MK-7) supplementation on cardiovascular, metabolic, and bone health.
Who can participate
Age range50 Years – 85 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Detectable CAC (Agatson score \>=10) assessed by Cardiac Computed Tomography (CT) scan in the Inter99 20-year follow-up study
Exclusion Criteria:
* Manifest CVD (prior cerebral infarct, prior myocardial infarct, prior percutaneous coronary intervention or prior coronary artery bypass surgery)
* Noise on the CT scan, which complicates an accurate assessment of CAC and interpretation of the CT scan. An example is a pacemaker
* Current treatment with Vitamin K antagonist (VKA).
* History of coagulation disorders (hemophilia, von Willebrand disease, sickle cell anemia)
* Active malignant disease (ongoing treatment)
* Previous surgical removal of the thyroid gland, or one or more of the parathyroid glands
* Regular use of vitamin K supplements other than trial tablets
* Pregnancy or breastfeeding